/>

Monday, April 29, 2019

NEWS 29 April 2019

NEWS FROM USA

NEW GENERICS LAUNCHES IN US

 DRUG

COMPANY

Corresponding RLD

Annual sales quoted in press release as per IQVIA 

Press Release

Cefazolin injections (10 GM/vial)

Apotex

Ancef

N/A

Link

 

NDA APPROVALS (New combination)

 

Approval Date

Product Name

NDA Sponsor

Brand Name

Prescribing information

25 Apr 2019

Halobetasol Propionate (0.01%)/Tazarotene (0.045%) lotion

Bausch

Duobrii

Link

 

ANDA APPROVALS

 

Approval Date

Drug Product

ANDA

Sponsor

Corresponding RLD

Number Of Other Approved Generics

23 Apr. 2019

Rufinamide oral suspension

Bion pharma

Banzel

(Eisai)

None

Hikma

24 Apr. 2019

Testosterone Cypionate injections

Wilshire pharma

Depo-Testosterone (RS)

Eight

24 Apr. 2019

Rosuvastatin Calcium tablets

Sciegen pharma

Crestor

(IPR)

More than 20

24 Apr. 2019

Cisatracurium besylate injections

Somerset therapeutics

Nimbex

(Abbvie)

Four

24 Apr. 2019

Pentamidine isethionate inhalant

Seton Pharma

Nebupent*

(Fresenius Kabi)

None

24 Apr. 2019

Teriflunomide Tablets

MSN 

Aubagio

(Sanofi)

Six

24 Apr. 2019

Medroxyprogesterone acetate injections

Sun Pharma

Depo-Provera (Pharmacia)

Four

24 Apr. 2019

Methylphenidate ER tablets

Andor Pharma

Concerta

(Janssen)

Six

24 Apr. 2019

Leflunomide tablets

Zydus

Arava

(Sanofi)

Five

25 Apr. 2019

Daunorubicin injections

Hisun Pharma

Cerubidine

(West-Ward)

Fresenius Kabi

25 Apr. 2019

Linezolid tablets

Celltrion

Zyvox

(Pharmacia)

Ten

25 Apr. 2019

Cisatracurium besylate injections

Nanjing-King friend

Nimbex

(Abbvie)

Four

25 Apr. 2019

Cisatracurium besylate injections preservative free

Nanjing-King friend

Nimbex Preservative free

(Abbvie)

Four

25 Apr. 2019

Clarithromycin tablets

Ajanta

Biaxin

(Tablets)

Eight

*Nebupent was mentioned in FDA’s latest off-patent off-exclusivity products without an approved generic list. 

USFDA INSPECTIONS:

Torrent Pharma provides update on USFDA audit at Indrad plant.

-      The inspection was conducted by USFDA in April 2019.

-      As per the press release, the Indrad facility has received certain observations which are procedural in nature and the Company is confident of addressing them satisfactorily.

-      Full Press release: Link

If you have any query/suggestion then please write us at pharmacaption@gmail.com

Wednesday, April 24, 2019

NEWS 24 APR 2019

NEWS FROM USA
NEW GENERICS LAUNCHES IN US
 DRUG
COMPANY
Corresponding RLD
Annual sales quoted in press release as per IQVIA 
Press Release
Solifenacin Succinate Tablets
Teva
VESIcare
$955 Million

505(b)2 NDA APPROVALS

Approval Date
Product Name
NDA Sponsor
Brand Name
Prescribing information
16 Apr 2019
Cysteine Hydrochloride Injection
Exela Pharma 
Elcys

OTHER NDA APPROVALS
Approval Date
Product Name
NDA Sponsor
Brand Name
Prescribing information
22 Apr 2019
Ivabradine Solution
Amgen Inc
Corlanor

ANDA APPROVALS

Approval Date
Drug Product
ANDA
Sponsor
Corresponding RLD
Number Of Other Approved Generics
19 Apr 2019
Custopharm Inc
Valstar Preservative Free
(Endo)
None
19 Apr 2019
Cadila Pharms
Starlix
 (Novartis)
Six
19 Apr 2019
Pharm Sourcing
Canasa
(Allergan)
One
(Mylan)
19 Apr 2019
Ingenus 
Tricor 
(Abbvie)
Eight
19 Apr 2019
Aurobindo 
Augmentin 125
(Neopharma)
Three
19 Apr 2019
Alembic 
Aubagio
(Sanofi)
Four
19 Apr 2019
Everolimus Tablets for suspension
Mylan 
Afinitor Disperz (Novartis)
None
19 Apr 2019
Alembic 
Tobrex (Novartis)
Five
22 Apr 2019
Taro 
Men's Rogaine
(Johnson And Johnson)
Two
22 Apr 2019
Taro 
Men's Rogaine
(Johnson And Johnson)
Two
22 Apr. 2019
Specgx 
Adderall XR 5
(Shire)
Five

TENTATIVE ANDA APPROVALS
Approval Date
Drug
Company
18 Apr 2019
Ezra Ventures 
19 Apr 2019
Accord Hlthcare 
19 Apr 2019
Gland Pharma 
23 Apr 2019
West-Ward 

TENTATIVE NDA APPROVALS
Approval Date
Drug
Company
18 Apr 2019
SUN PHARMA 

USFDA INSPECTIONS:
U.S. FDA classifies the inspection of Lupin's Pithampur (Indore) Unit-2 facility as OAI.
-      The inspection was conducted by USFDA in January 2019.
-      As per the press release, the Company does not believe that this classification will have an impact on disruption of supplies or the existing revenues from operations of this facility.
-      Full Press release: Link
USFDA retains the OAI status of Indoco's Goa Plant I
-      This is the Finished dosages facility situated in Goa.
-      The inspection was conducted by USFDA in January 2019.
-      As per press release, the company believe that this OAI status will not impact their current commercial supplies to USA or revenues from this manufacturing facility
-      Full Press release: Link
If you have any query/suggestion then please write us at pharmacaption@gmail.com